Second‐line lurbinectedin as a new treatment option for small‐cell lung cancer: Preliminary results in real‐clinical practice
Abstract Introduction Few strategies exist for treatment of patients with small‐cell lung cancer (SCLC) extended‐stage after failure of first‐line platinum‐based chemotherapy. Lurbinectedin is a novel RNA‐polymerase‐II inhibitor investigated as a second‐line therapy for SCLC. However, its efficacy a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14464 |